Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) H2 2025 Earnings call March 23, 2026 08:00 AM ET Company ParticipantsDing Nanchao - Deputy General Manager and Chief Marketing OfficerGe Junyou - President and CEOJinbo Zhang - Director of the Analytical DepartmentMatthew Culley - Portfolio ManagerWei Chen - Deputy General Manager and VP of Molecule R&DXiangyang Tan - Chief Scientific OfficerXiao Ping Jin - Chief Medical OfficerZe Jian Zhou - CFOConference Call ParticipantsShen Ziyi - Equity Research Anal ...

摩·咨询 查数据·找摩熵 摩炳咨询 医药行业观察周报 2026.03.09-2026.03.15 摩熵·咨询 摩咨询一医药行业观察周报 查数据·找摩 目录 | 本周国内创新药/改良型新药申请临床/获批临床/申请上市/获批上市数据分析。 | | | --- | --- | | 1.1总体概况 | | | 1.2本周获批临床创新药/改良型新药信息速览(不含补充申请) | | | 1.3本周获批上市创新药信息速览 | 10 | | 、本周国内仿制药/生物类似物申报/审批数据分析。 | 10 | | 2.1总体概况， | 10 | | 2.2本周通过/视同通过一致性评价全局分析. | 11 | | 2.3本周首次过评/视同过评、过评/视同过评达7 家品种盘点 | 12 | | 三、本周国内医药大健康行业政策法规汇总 | 13 | | 3.1本周国内医药大健康行业政策法规速览 | .13 | | 3.2本周重点行业政策详细说明， | .14 | | 》国家药监局综合司关于学习宣传贯彻《中华人民共和国药品管理法实施条例》的通知 | .14 | | 四、本周全球创新药研发概览 | .14 | | 4.1本周全球TOP10创 ...

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% this week, ranking 13th out of 31 sectors, and a year-to-date decline of 0.13%, ranking 23rd out of 31 sectors [8]. - A significant milestone was achieved with the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration, marking a transition from technical exploration to clinical application [9]. - The launch of a national major science and technology project for innovative drugs targeting Alzheimer's disease indicates a strong governmental focus on drug development for critical diseases in the central nervous system [10]. Summary by Sections 1. Market Observation - The pharmaceutical and biotechnology sector has seen a decline of 0.22% this week and 0.13% year-to-date, indicating a market correction [8]. 2. Industry Dynamics 2.1 Brain-Computer Interface Milestone - The approval of the brain-computer interface system by the National Medical Products Administration represents the first global launch of an invasive medical device, aimed at assisting patients with cervical spinal cord injuries [9]. 2.2 Alzheimer's Disease Drug Development - The initiation of a national project for innovative Alzheimer's drugs highlights the importance of addressing urgent clinical needs in the central nervous system, potentially leading to technological breakthroughs and industrial advancements [10]. 3. Company Dynamics 3.1 Kanglong Chemical - Kanglong Chemical announced a strategic partnership with Eli Lilly for the commercialization of the oral GLP-1 drug Orforglipron, receiving a $200 million investment to enhance its technical capabilities [11]. 3.2 Laika Pharmaceutical - Laika Pharmaceutical successfully completed Phase I SAD studies for LAE102 in the U.S. and is planning Phase II trials, indicating accelerated global development [12]. 3.3 Hotgen Biotech - Hotgen Biotech's innovative drug SGC001 has completed its first administration in Phase II clinical trials for heart attack treatment, marking significant progress in its development [13]. 3.4 East China Pharmaceutical - East China Pharmaceutical's HDM2024 has received FDA approval for Phase I clinical trials, targeting advanced solid tumors, enhancing its competitive position in oncology [14]. 3.5 Kelun Pharmaceutical - Kelun Pharmaceutical's SKB575 has been approved for clinical trials targeting atopic dermatitis, showcasing its potential as a best-in-class treatment with a long dosing interval [15]. 4. Areas of Focus - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector for potential investment opportunities [16].

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% this week, ranking 13th out of 31 sectors, and a year-to-date decline of 0.13%, ranking 23rd out of 31 sectors [8]. - A significant milestone was achieved with the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration, marking a transition from technical exploration to clinical application, which opens commercial opportunities in the field of neuroregulation and implantable medical devices [9]. - The launch of a national major scientific research project for innovative drugs targeting Alzheimer's disease indicates the government's commitment to addressing urgent clinical needs in the central nervous system, potentially accelerating technological breakthroughs and industrialization in this area [10]. Company Dynamics - Kanglong Chemical announced a strategic partnership with Eli Lilly for the commercialization of the oral GLP-1 drug Orforglipron, receiving a $200 million investment to enhance its technical capabilities [11]. - Laika Pharmaceuticals successfully completed Phase I SAD studies for LAE102 in the U.S. and is planning Phase II trials, indicating progress in global development [12]. - Hotgen Biotech's innovative drug SGC001 has completed its first administration in Phase II clinical trials for treating acute myocardial infarction, marking a significant advancement in this therapeutic area [13]. - East China Pharmaceutical's self-developed dual-target ADC drug HDM2024 has received FDA approval for Phase I clinical trials in the U.S., enhancing its competitiveness in the oncology field [14]. - Kelun Biotech's SKB575 has been approved for clinical trials targeting atopic dermatitis, showcasing its potential as a best-in-class treatment with a long dosing interval [15]. Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector for potential investment opportunities [16].